SCINTIMUN

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug SCINTIMUN contains one active pharmaceutical ingredient (API):

1	Besilesomab UNII 538316W9ZU - BESILESOMAB
	Besilesomab is a murine immunoglobulin of IgG1 isotype that specifically binds to NCA-95 (non specific cross-reacting antigen 95), an epitope expressed at the cell membrane of granulocytes and granulocyte precursors. Besilesomab cross-reacts with tumours expressing carcinoembryonic antigen (CEA).
	Read more about Besilesomab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SCINTIMUN Kit for radiopharmaceutical preparation	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09HA03	Technetium (99mTc) antigranulocyte antibody	V Various → V09 Diagnostic radiopharmaceuticals → V09H Inflammation and infection detection → V09HA Technetium (99mTc) compounds
Discover more medicines within V09HA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1458907, 1458918
ES	Centro de información online de medicamentos de la AEMPS	09602002
FR	Base de données publique des médicaments	68516450
GB	Medicines & Healthcare Products Regulatory Agency	394714
IT	Agenzia del Farmaco	040281014, 040281026
LT	Valstybinė vaistų kontrolės tarnyba	1052911, 1052912
PL	Rejestru Produktów Leczniczych	100316444